Acquisition of an Illumina NextSeq 500 and associated ancillary hardware and software
The Centers for Disease Control and Prevention (CDC), National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), intends to award a sole source contract to Illumina, Inc. 9885 Town Centre Drive, San Diego, CA 92121 for the acquisition of Illumina NextSeq 500 and associated ancillary hardware and software for high throughput sequencing of enteric disease isolates.
The statutory authority for this sole source acquisition is 10 U.S.C 2304(c)(1) in accordance with FAR Part 6.302-1- only one responsible source and no other supplies or services will satisfy the agency requirement. The NAICS code for this procurement is 334516, Analytical Laboratory Instrument Manufacturing. The period of performance for this procurement is 12 months.
The Illumina NextSeq 500 will be used for enteric disease laboratory investigations in NCEZID using next generation sequencing. The Enterics Disease Laboratory Branch (EDLB) has performed classic biochemical, phenotypic, and gel-electrophoresis based testing to characterize isolate samples. The advent of next-generation whole-genome sequencing has made rapid, inexpensive and accurate whole genome sequencing of bacterial isolates in real time a possibility. This method provides far greater resolution than any existing biochemical, phenotypic, or gel-based test, as well as comparable data across samples separated by time and geography. Next generation sequencing enables the simultaneous capture of information about variation, virulence, antibiotic resistance, and origin. Following the successful deployment of this approach on listeria isolate samples, EDLB seeks to expand next-generation sequencing to other enteric disease isolates. This requires the use of high-throughput, user-friendly sequencing devices capable of sequencing several hundred samples in a week. The only sequencer that provides this level of throughput, ease of use, sequencing efficiency, and sequencing accuracy is the Illumina NextSeq 500.
When compared to other next-generation sequencers, the Illumina NextSeq 500 is unique in that it offers high throughput and a high degree of sequencing accuracy at low cost. Additionally, its high rate of image capture and independent lane fluidics allow the capture of a large quanitity of long base pair reads in 24 hours. The NextSeq 500 also offers a flexible and easy to use interface and self-contained reagent cartridge format that minimizes contamination and increases ease of use. Finally, it offers support for up to 96 index barcodes allows for more samples to be run on than on other comparable sequencers.
Manufacturers of other next-generation sequencing devices were evaluated. Other systems that were found are unable to generate a comparable quantity of data or acceptable sequencing accuracy. The only sequencer that provides this level of throughput, ease of use, sequencing efficiency, and sequencing accuracy is the Illumina NextSeq 500.
As a result of this synopsis, no competitive solicitation will be posted on FedBizOpps. We will issue only one solicitation to Illumina, Inc.. However, all responsible sources that believe they can meet these requirements may submit their capabilities/qualifications statement to provide the services to LeslieJones via email ONLY at [email protected] with the solicitation number 69538 referenced in the subject line NO LATER THAN June 23, 2014.
A determination by the Government not to compete this proposed action will be based on responses to this notice and are solely within the discretion of the Contracting Officer. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.
Leslie D. Jones, Phone 7704882042, Email [email protected]
